Nimbus Therapeutics Secures $210M Private Financing To Advance Next Wave Of Tech-Enabled Small Molecule Medicines
Amount Raised
$210 Million
Round Type
Funding Round
BostonBiotechnologyHealth CareTherapeuticsPharmaceuticalInvestors
Description
Nimbus Therapeutics, LLC ("Nimbus Therapeutics” or “Nimbus”), a clinical-stage company that designs and develops breakthrough medicines through its powerful computational drug discovery engine, today announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines. The round was co-led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture, with participation from another new investor that is a U.S.-based life sciences-focused fund as well as existing investors Bain Capital Life Sciences, BVF Partners L.P., Gates Frontier, Lightstone Ventures, Pfizer Ventures, RA Capital Management, and SV Health Investors.
Who to call at Nimbus Therapeutics, and when
A new round usually means Nimbus Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nimbus Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nimbus Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nimbus Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nimbus Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Nimbus Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.